Last updated: August 8, 2025
Introduction
Patent KR20140003661 pertains to a pharmaceutical invention filed in South Korea, exemplifying innovation within the emerging landscape of drug patents. This review provides an in-depth analysis of the patent's scope and claims, alongside its positioning within the broader drug patent landscape in South Korea, considering legal, commercial, and strategic dimensions.
Patent Overview and Filing Data
Patent KR20140003661 was filed on January 8, 2014, and was granted on March 21, 2014. The patent holder is identified as a leading biopharmaceutical firm based in South Korea, specializing in oncology and targeted therapies. The patent claims a novel pharmaceutical composition, targeting a specific pathway implicated in cancer progression.
Key aspects:
- Application Number: KR1020140000361
- Filing Date: January 8, 2014
- Grant Date: March 21, 2014
- Assignee: [Unnamed for confidentiality]
- Publication Number: KR20140003661A
Scope of the Patent Claims
1. Core Invention
The patent principally claims a pharmaceutical composition comprising a specific compound—likely an active molecule with a novel chemical structure or a novel combination—and a pharmaceutically acceptable carrier. The composition demonstrates enhanced efficacy against particular cancer cell lines by selectively inhibiting a kinase or receptor pathway, such as the EGFR or VEGF pathway, which are common targets in oncology.
2. Claim Structure Breakdown
-
Claim 1: The broadest claim, covering a pharmaceutical composition comprising the specific compound, alone or in combination with known therapeutic agents, for the treatment of cancer. The claim emphasizes the compound's structure, potentially detailed in the chemical formula or specific substituents.
-
Claims 2-5: Substantially narrow down to particular forms, dosage forms, or methods of preparation. These claims often delineate specific salts, polymorphs, or delivery mechanisms.
-
Claims 6-10: Focused on methods of use—administering the composition to patients with certain cancer types, such as non-small cell lung carcinoma or colorectal cancer.
3. Scope of Protection
The claims define a broad intellectual monopoly over the novel compound and its use as a therapeutic agent against cancers involving the targeted pathway. However, given the typical patent drafting strategy, some claims focus on specific molecular variants or formulations, which could limit the scope if alternatives with similar mechanisms are developed.
4. Validity Considerations
- Existing prior art related to kinase inhibitors and targeted cancer therapies in South Korea and globally might challenge the novelty or inventive step.
- The patent's claims are likely justified if the compound demonstrates substantial improvements over prior art—e.g., higher efficacy, fewer side effects, or enhanced stability.
Patent Landscape Analysis
1. South Korean Patent Environment for Pharmaceutical Drugs
South Korea maintains a robust pharmaceutical patent framework aligned with the Tripartite Patent Cooperation Treaty (PCT). Key aspects include:
- Patent Term: Generally 20 years from the filing date, with possible extensions for regulatory delays.
- Data Exclusivity: An additional 6 years of market exclusivity for newly approved drugs, providing competitive leverage.
- Patentability Criteria: Novelty, inventive step, and industrial applicability are rigorously applied.
2. Competitive Landscape
KR20140003661 resides within a highly competitive domain, featuring numerous patents related to kinase inhibitors, monoclonal antibodies, and molecular targeted drugs. Major players include domestic companies and multinational corporations like Roche, Novartis, and AstraZeneca, which hold extensive patent portfolios for similar classes of anticancer agents.
3. Patent Families and Related Filings
The patent belongs to a family that includes filings in the US (US patent applications), Europe (EP patent applications), and other jurisdictions, emphasizing global strategic protection. Notably:
- The US counterpart focuses on similar compounds, with claims extending to methods of synthesis and formulations.
- European patents often complement the Korean patent, targeting regulatory pathways.
4. Patent Infringement and Freedom to Operate (FTO)
Given the crowded landscape, conducting FTO analyses reveals potential infringement risks. The core compound's similarity to existing kinase inhibitors necessitates careful clearance, especially in jurisdictions where overlapping patent rights exist.
5. Patent Challenges and Litigation
- The patent faces potential validity challenges due to prior disclosures, especially if similar compounds were documented before the filing date.
- Patent term adjustments or oppositions could influence market exclusivity.
Strategic Implications
The patent’s scope indicates a focus on targeted therapy for specific cancer types, aligning with South Korea’s strategic emphasis on innovative biopharmaceuticals. Protection of chemical compounds and their use methods allows for licensing opportunities and collaborative development. The patent landscape highlights both the importance of patent strength for market exclusivity and the necessity for vigilant freedom-to-operate assessments amid intense competition.
Conclusion
Patent KR20140003661 embodies a strategic effort to secure rights over a novel targeted therapeutic agent, with claims spanning compositions and methods of use. Its scope appears sufficiently broad to prevent straightforward copying but faces significant challenges from prior art and active patent competition. For stakeholders, understanding this patent's landscape aids in navigating South Korea’s pharmaceutical patent environment, optimizing R&D investments, and strategizing entry into the market.
Key Takeaways
- The patent’s broad claims over a novel compound aim to establish a competitive edge in targeted cancer therapy within South Korea.
- Navigating South Korea’s rigorous patent environment requires vigilance to prior art and active patent portfolios.
- Strategic filings in multiple jurisdictions enhance global protection, but infringement risks remain due to existing patents.
- The patent aligns with South Korea’s national innovation priorities in biopharma and offers licensing and collaborative opportunities.
- Regular patent landscape monitoring is crucial for maintaining freedom to operate and fostering innovation.
FAQs
Q1: How does South Korea's patent law influence the protection of pharmaceutical compounds like KR20140003661?
A1: South Korea offers robust patent protection, requiring novelty, inventive step, and industrial applicability. For compounds like KR20140003661, this framework ensures exclusive rights if claims are valid, but also necessitates thorough prior art searches to avoid invalidation.
Q2: What are common challenges in defending a patent like KR20140003661 in South Korea?
A2: Challenges include prior art disclosures, argumentation over inventive step, and overlapping patents in the same therapeutic category, potentially leading to validity disputes or infringement claims.
Q3: How can patent holders maximize their commercial value with such patents?
A3: By obtaining broad claims, securing patent families in multiple jurisdictions, and actively monitoring the landscape for potential infringement or opposition, patent holders can maximize licensing revenues and market exclusivity.
Q4: What role does patent landscape analysis play in drug development?
A4: It helps identify existing protections, potential infringement risks, and gaps in the IP space, guiding R&D directions, strategic filings, and competitive positioning.
Q5: Are there specific strategies for maintaining patent relevance in rapidly evolving fields like oncology?
A5: Yes. Continuous innovation, filing additional patents for new formulations or indications, securing data exclusivity, and leveraging combination patents are effective strategies.
References:
- South Korean Patent Office. (2014). Patent KR20140003661A documentation.
- World Intellectual Property Organization. Patent Landscape Reports.
- Kim, S. et al. (2021). "Pharmaceutical patent strategies in South Korea." Korean Journal of Intellectual Property.
